 |
| Coronavirus Treatment Drugs Market |
The Coronavirus Treatment Drugs market is estimated to be valued at US$ 25812.99 Mn or Mn in 2023 and is expected to exhibit a CAGR of 17.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The coronavirus treatment drugs market covers drugs and treatments used for
coronavirus disease. Some key product types include antiviral drugs such as
remdesivir and favipiravir, immune system modulators, and monoclonal antibody
therapies. Coronavirus disease causes respiratory illness and governments and
pharma companies are investing heavily in the research and development of
effective drugs for the treatment of the disease.
Market Dynamics:
Rising prevalence of coronavirus disease across the globe is driving the demand
for effective treatment drugs for the disease. According to WHO, there have
been over 495 million confirmed cases of coronavirus disease till November
2022. Further, lack of availability of vaccine in underdeveloped and developing
countries is also contributing to the spread of the disease. This is expected
to boost the coronavirus treatment drugs market over the forecast period.
Another factor aiding the market growth is ongoing research and clinical trials
for development of new and more effective drugs for coronavirus treatment. For
instance, phase 3 clinical trials are underway for various monoclonal antibody
therapies such as sotrovimab and bebtelovimab. Positive outcomes of such trials
are likely to provide momentum to the market in the coming years.
SWOT Analysis
Strength: The coronavirus treatment drugs market has strong growth potential
due to the ongoing pandemic. Major companies are investing heavily in R&D
to develop effective treatment drugs. Many potential drugs are in pipeline
which can aid recovery.
Weakness: Developing new drugs require extensive clinical trials and approvals
which are costly and time taking. Current drugs have shown side effects in some
patients. Alternative treatment methods like vaccines are also available.
Opportunity: Increasing cases of new coronavirus variants can boost demand for
improved treatment options. Government support and initiatives will provide
impetus to firms for research and development activities. Emerging economies
present large patient pool and market scope.
Threats: Patent expiration of blockbuster drugs will increase competition.
Alternative non-drug therapies may gain traction. Stringent regulations can
delay drugs approval or market entry.
Key Takeaways:
The global Coronavirus
Treatment Drugs Market Share size is expected to witness high growth,
exhibiting CAGR of 17% over the
forecast period, due to increasing research investments from pharmaceutical
players. Major companies are injecting funds to develop newer treatment options
with lower side effects.
Regional analysis: North America dominates the global market, owing to rising
cases, strong healthcare infrastructure, and presence of major pharmaceutical
manufacturers in the region. However, Asia Pacific is anticipated to manifest
the fastest growth due to large patient base, increasing healthcare spending,
and growing penetration of global players in emerging economies like India and
China
Key players operating in the coronavirus treatment drugs market include Serum
Institute of India, Pfizer Inc., AstraZeneca plc., Bharat Biotech International
Limited, Cadila Healthcare Limited, Johnson & Johnson, Moderna,
GlaxoSmithKline plc., CanSino Biologics, Sinovac Biotech, Novavax, Inc.,
Glenmark Pharmaceuticals Limited, Dr. Reddy's Laboratories, and Merck &
Co., Inc. These players are involved in various strategic alliances such as
mergers, acquisitions, and collaborations to strengthen their market position.
Read More,
0 Comments